Page 1,922«..1020..1,9211,9221,9231,924..1,9301,940..»

Human Embryonic Stem Cell Research Remediation Project Final – Video

Posted: November 28, 2014 at 5:40 pm


Human Embryonic Stem Cell Research Remediation Project Final
ENC 1101 Human Embryonic Stem Cell Research Remediation Project.

By: Andrew Boulos

Originally posted here:
Human Embryonic Stem Cell Research Remediation Project Final - Video

Posted in Stem Cell Research | Comments Off on Human Embryonic Stem Cell Research Remediation Project Final – Video

Global Cell Expansion Market Research Report 2019 – Video

Posted: November 28, 2014 at 5:40 pm


Global Cell Expansion Market Research Report 2019
New Market Research Report on Cell Expansion Market by Product (Reagent, Media, Serum, Bioreactors, Centrifuge), Cell Type (human, animal), Application (Stem Cell Research, Regenerative...

By: David clark

Read more from the original source:
Global Cell Expansion Market Research Report 2019 - Video

Posted in Stem Cell Research | Comments Off on Global Cell Expansion Market Research Report 2019 – Video

Stranger Donates Stem Cells In Hopes Of Curing New York Woman With Leukemia

Posted: November 28, 2014 at 11:01 am

CBS New York (con't)

Affordable Care Act Updates: CBSNewYork.com/ACA

Health News & Information: CBSNewYork.com/Health

NEW YORK (CBSNewYork) A New York woman battling leukemia was especially grateful this Thanksgiving, as she credited the kindness of a total stranger with helping save her life.

They found the donor, and it was just basically like a weight lifted off my shoulders, said Jeanine Walsh, 38.

As CBS2s Dr. Max Gomez reported Thursday, Walsh the mother of two young children has been battling leukemia for the second time in two years.

I was in total and complete shock, she said.

No members of Walshs family were a match for her, but a willing donor was found through the national registry. Peripheral stem cells were collected from the donor, located in the Western U.S., earlier this week.

The process took just a few hours.

We attach the patient, that is the donor, to a machine. The machine takes blood form the donor, filters out the stem cells if you will, and returns the rest of the blood to the donor, said Dr. Michael Schuster, director of stem cell transplantation at Stony Brook University Hospital.

See the original post here:
Stranger Donates Stem Cells In Hopes Of Curing New York Woman With Leukemia

Posted in New York Stem Cells | Comments Off on Stranger Donates Stem Cells In Hopes Of Curing New York Woman With Leukemia

Cardio3 BioSciences Announces the Nomination of Three Co-Principal Investigators for Its CHART-2 Phase III Clinical …

Posted: November 28, 2014 at 10:59 am

CHART-2 is Cardio3 BioSciences second Phase III trial for C-Cure, the first and only stem cell therapeutic using guided stem cells for the condition of congestive heart failure. C-Cure is currently in a Phase III clinical trial in Europe (CHART-1). The CHART-2 Phase III trial is a prospective, multi-centre, randomized, sham-controlled, patient- and evaluator-blinded study comparing treatment with C-Cure to a sham treatment. The trial is designed to recruit a minimum of 240 patients with chronic advanced symptomatic heart failure.

In a clinical trial, the Principal Investigator (PI) is responsible for the scientific and medical supervision of the trial. The PI reviews the protocol, oversees the implementation of the trial at all the investigational sites, and provides guidance as to the integrity and the interpretability of the data generated during the trial.

Dr Christian Homsy, CEO of Cardio3 BioSciences, said: Cardio3 BioSciences is very proud to count three such prominent physicians as the Co-Principal Investigators of its phase III clinical study for C-Cure authorized in the United States. The medical community is eagerly waiting for a solution for the treatment of heart failure patients, and CHART-2 is a promising avenue towards treating this disease. We selected three prominent cardiologists with established reputations and their acceptance to lead our clinical trial is further recognition of the potential of C-Cure as future treatment of heart failure.

*** END ***

To subscribe to Cardio3 BioSciences newsletter, visit http://www.c3bs.com. Follow us on Twitter @Cardio3Bio.

About CHART-2 CHART-2, the Company's second Phase III clinical trial, is intended to assess in the US, the efficacy of C-Cure as a treatment for heart failure of ischemic origin. CHART-2 is designed as a prospective, multi-centre, randomized, sham-controlled, patient- and evaluator-blinded study comparing treatment with C-Cure to a sham treatment. The trial is aimed to recruit a minimum of 240 patients with chronic advanced symptomatic heart failure. The primary endpoint of the trial is the Six Minute Walk Test post-procedure, a commonly used index of cardiovascular performance.

About C-Cure Cardio3 BioSciences C-Cure therapy involves taking stem cells from a patients own bone marrow and through a proprietary process called Cardiopoiesis, re-programming those cells to become heart cells. The cells, known as cardiopoietic cells, are then injected back into the patients heart through a minimally invasive procedure, with the aim of repairing damaged tissue and improving heart function and patient clinical outcomes. C-Cure is the outcome of multiple years of research conducted at Mayo Clinic (Rochester, Minnesota, USA), Cardio3 BioSciences (Mont-Saint-Guibert, Belgium) and Cardiovascular Centre in Aalst (Aalst, Belgium).

About Mayo Clinic Recognizing 150 years of serving humanity in 2014, Mayo Clinic is a non-profit worldwide leader in medical care, research and education for people from all walks of life. For more information, visit http://www.150years.mayoclinic.org ; http://www.mayoclinic.org ; and http://www.newsnetwork.mayoclinic.org . Mayo Clinic has a financial interest in Cardio3 Biosciences.

About Cardio3 BioSciences Cardio3BioSciences is a Belgian leading biotechnology company focused on the discovery and development of regenerative and protective therapies for the treatment of unmet medical needs. The company was founded in 2007 and is based in the Walloon region of Belgium. Cardio3BioSciences leverages research collaborations in the US and in Europe with Mayo Clinic and the Cardiovascular Centre Aalst, Belgium. The Companys lead product candidate C-Cure is an innovative pharmaceutical product that is being developed for heart failure indication. C-Cure consists of a patients own cells that are harvested from the patients bone marrow and engineered to become new heart muscle. This process is known as Cardiopoiesis. Cardio3BioSciences has also developed C-Cathez, the most technologically advanced injection catheter with superior efficiency of delivery of bio therapeutic agents into the myocardium. Cardio3 BioSciences shares are listed on Euronext Brussels and Euronext Paris under the ticker symbol CARD.

C3BS-CQR-1, C-Cure, C-Cathez, Cardio3 BioSciences and the Cardio3 BioSciences and C-Cathezlogos are trademarks or registered trademarks of Cardio3 BioSciences SA, in Belgium, other countries, or both. Mayo Clinic holds equity in Cardio3 BioSciences as a result of intellectual property licensed to the company. In addition to historical facts or statements of current condition, this press release contains forward-looking statements, which reflect our current expectations and projections about future events, and involve certain known and unknown risks, uncertainties and assumptions that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks, uncertainties and assumptions could adversely affect the outcome and financial effects of the plans and events described herein. These forward-looking statements are further qualified by important factors, which could cause actual results to differ materially from those in the forward-looking statements, including timely submission and approval of anticipated regulatory filings; the successful initiation and completion of required Phase III studies; additional clinical results validating the use of adult autologous stem cells to treat heart failure; satisfaction of regulatory and other requirements; and actions of regulatory bodies and other governmental authorities.

Link:
Cardio3 BioSciences Announces the Nomination of Three Co-Principal Investigators for Its CHART-2 Phase III Clinical ...

Posted in Minnesota Stem Cells | Comments Off on Cardio3 BioSciences Announces the Nomination of Three Co-Principal Investigators for Its CHART-2 Phase III Clinical …

Blood test could pick up risk of cancer five years in advance, say Harvard scientists

Posted: November 28, 2014 at 10:59 am

"People often think about disease in black and white - that there's 'healthy' and there's 'disease' - but in reality most disease develops gradually over months or years, said assistant professor and senior author Steven McCarroll at Harvard Medical School.

The mutations are thought to originate in blood stem cells, which then produce mutated cells which reproduce at an accelerated rate until they account for a large fraction of the cells in a person's blood.

"Cancer is the end-stage of the process," said Siddhartha Jaiswal, a Broad associated scientist and clinical fellow from Massachusetts General Hospital who was first author of Ebert's paper.

"By the time a cancer has become clinically detectable it has accumulated several mutations that have evolved over many years. What we are primarily detecting here is an early, pre-malignant stage in which the cells have acquired just one initiating mutation."

Individuals with these mutations had a higher risk of Type 2 diabetes, coronary heart disease, and ischemic stroke as well.

The researchers involved emphasised that there is no clinical benefit today for testing for the mutations as there are currently no treatments that can prevent blood cancer.

However, they say the results open the door to entirely new directions for blood cancer research, toward early detection and even prevention.

"The results demonstrate a way to identify high-risk cohorts - people who are at much higher than average risk of progressing to cancer - which could be a population for clinical trials of future prevention strategies," added Prof McCarroll.

"The abundance of these mutated cells could also serve as a biomarker - like LDL cholesterol is for cardiovascular disease - to test the effects of potential prevention therapies in clinical trials."

The research was published in New England Journal of Medicine.

More here:
Blood test could pick up risk of cancer five years in advance, say Harvard scientists

Posted in Massachusetts Stem Cells | Comments Off on Blood test could pick up risk of cancer five years in advance, say Harvard scientists

Running keeps you young: Study

Posted: November 27, 2014 at 2:52 pm

Im sure most of you could have guessed that regular walking and running can keep you young, but you might surprised just how much

Researchers at the University of Colorado found that people over 65 who run or walk several times a week expend as much energy as a typical 20-year-old. The study said that runners get more benefits than walkers, but that walking does help fend off diabetes, depression, and heart disease.

Source: kdvr.com

A new study from Ohio State University found that saturated fat in your diet does not drive up levels of saturated fat in your blood, however, carbohydrates do. Researchers said that reducing carbs and adding fat to the diet in a well-formulated way will make the body burn the saturated fat first, so it wont be stored.

Source: news.osu.edu

Researchers at the University of Southern California have found a mature stem cell that appears to be able to perform two different tasks. The cells normally grow fingernails and skin, but when signaled by a special protein called Bone Morphogenic Protein, they switched to focusing on nail repair.

Scientists are now trying to figure out if sending that signal to other stem cells can cause them to perform more tasks, which could help with finger repair and maybe even re-grow amputated fingers.

Its not as sci-fi as you think unborn babies can already re-grow body parts, and children as old as nine or ten have been known to re-grow fingertips all on their own.

Read this article:
Running keeps you young: Study

Posted in Colorado Stem Cells | Comments Off on Running keeps you young: Study

Ageless Derma Introduces Their Latest Innovation: Swiss Apple Stem Cell Mask

Posted: November 27, 2014 at 2:52 pm

Irvine, California (PRWEB) November 27, 2014

The Ageless Derma skin care company has just released their latest development in the form of a facial mask that exfoliates skin with ingredients such as apple stem cells to renew the complexion and correct texture and tone. The companys Swiss Apple Stem Cell Mask incorporates the cells of a long-living rare apple with other revitalizing ingredients from nature to result in a gentle mask that is effective and calming.

The Swiss apple, Malus Domestica, has its beginnings that go as far back as 18th century Switzerland. Ageless Derma recognized the importance of this plants stem cell extract for its ability to keep the fruit fresh for extended periods of time without wrinkling or shriveling. The Swiss Apple Stem Cell Mask contains the scientific advances that come from the cultivation of these stem cells, having incorporated it into a powerful and effective facial mask to rejuvenate skin and keep wrinkles at bay.

The Swiss Apple Stem Cell Mask contains other natural ingredients that work together to keep skin at its purest and return youthful life to the complexion. Kaolin Clay from the earth absorbs toxins that can enter the skins surface due to environmental pollutants in the air. The clay helps draw out grime and purify skin. Sweet Almond Oil nourishes skin, and adds much needed moisture and smoothness. Safflower Oil improves the texture of skin; especially skin that has become roughened with time and sun exposure. The Safflower Oil in Swiss Apple Stem Cell Mask also locks in moisture and tones skin for a flawless and radiant complexion.

Ageless Derma added fruit extracts to the Swiss Apple Stem Cell Mask for added health and radiance. Pumpkin Fruit Ferment, Pineapple Enzyme, and Papaya Enzyme make this mask luscious and plush. Age-defying antioxidants are also included, with Green Tea Extract and Aloe Leaf Extract added for soothing and fighting free radicals.

The developers at Ageless Derma Skin Care know they are making something extraordinary happen. Their line of physician-grade skin care items incorporates an important philosophy: promoting overall skin health by delivering the most cutting-edge biotechnology and pure, natural ingredients to all of the skin's layers. This attitude continues to resonate to this day with the companys founder, Dr. Farid Mostamand, who nearly a decade ago began his journey to deliver the best skin care alternatives for people who want to have healthy and beautiful looking skin at any age. About this latest Ageless Derma product, Dr. Mostamand says, This natural enzymatic Swiss Apple Stem Cell Mask gently exfoliates dead skin cells that are blocking new cell turnover for a renewed and radiant complexion. This is accomplished without the use of unnatural chemicals that can harm your skins delicate balance.

Ageless Derma products are formulated in FDA-approved Labs. All ingredients are inspired by nature and enhanced by science. Ageless Derma products do not contain parabens or any other harsh additives, and they are never tested on animals. The company has developed five unique lines of products to address any skin type or condition.

View post:
Ageless Derma Introduces Their Latest Innovation: Swiss Apple Stem Cell Mask

Posted in California Stem Cells | Comments Off on Ageless Derma Introduces Their Latest Innovation: Swiss Apple Stem Cell Mask

Scientists use stem cells to correct skin defects

Posted: November 27, 2014 at 2:50 pm

New research has found evidence that stem cells could be used to correct genetic defects in skin and to treat certain rare diseases.

Three separate studies by scientists in the US, Europe and Japan have raised hopes that the methods could be used to develop treatments for a range of problems, including epidermolysis bullosa.

It is a disorder wheresufferers are born with extensive blistering and patches of missing skin.

They areleft with extremely fragile skin for all of their lives.

In the first study, the researchers used Induced Pluripotent Stem Cells (iPSCs) - adult cells that are reprogrammed to an embryonic stem cell-like state.

The scientists took diseased cells from three adult patients withepidermolysis bullosa.

The researchers converted the cells into iPSCs and used specialist tools to edit and fix the mutation in the genetic code responsible for defective collagen protein production, which causes the condition.

They then grew pieces of human skin that produced the correct collagen, and grafted them into mice where they lasted for three weeks.

It i's hoped the risk of rejection in humans will be minimal because the skin is made from the patient's own cells.

A second study confirmed these findings in the lab, showing that it is possible to genetically correct iPSCs from mice with epidermolysis bullosa and use the repaired cells to heal blistered skin.

Read more:
Scientists use stem cells to correct skin defects

Posted in Stem Cells | Comments Off on Scientists use stem cells to correct skin defects

Blistering skin disease may be treatable with 'therapeutic reprogramming,' researchers say

Posted: November 27, 2014 at 2:50 pm

PUBLIC RELEASE DATE:

26-Nov-2014

Contact: Krista Conger kristac@stanford.edu 650-725-5371 Stanford University Medical Center @sumedicine

Induced pluripotent stem cells made from patients with a form of blistering skin disease can be genetically corrected and used to grow back healthy skin cells in laboratory dishes, researchers at the Stanford University School of Medicine have found. They've termed the new technique "therapeutic reprogramming."

The skin cells formed normal human skin when grafted onto the backs of laboratory mice, they said.

The findings represent a major advance in the battle against the disease, epidermolysis bullosa, in which the top layer of skin, called the epidermis, sloughs off with the slightest friction, leaving open wounds that are difficult to heal. Severely stricken children who survive into their late teens or early 20s often die from invasive squamous cell carcinoma, a skin cancer that can arise during repeated cycles of skin wounding and healing.

"Epidermolysis bullosa is a truly horrible, debilitating skin disease in which the top layer of skin is not properly anchored to the underlying layers," said Anthony Oro, MD, PhD, professor of dermatology. "When they are born, the trauma of birth rips away their skin, and they continue to suffer severe skin wounds that require constant bandaging and medical attention throughout their lives."

Stanford has one of the largest epidermolysis bullosa clinics in the world, with an extremely active and engaged population of patients and their families eager to help researchers. The Stanford Department of Dermatology has been working to find new treatments for the disease for over 20 years. The latest advance, in which researchers replaced the mutated, disease-causing gene in the donor-made induced pluripotent stem cells with a healthy version, was funded by an $11.7 million grant from the California Institute for Regenerative Medicine.

New avenue of treatment

"This treatment approach represents an entirely new paradigm for this disease," Oro said. "Normally, treatment has been confined to surgical approaches to repair damaged skin, or medical approaches to prevent and repair damage. But by replacing the faulty gene with a correct version in stem cells, and then converting those corrected stem cells to keratinocytes, we have the possibility of achieving a permanent fix -- replacing damaged areas with healthy, perfectly matched skin grafts."

Read the rest here:
Blistering skin disease may be treatable with 'therapeutic reprogramming,' researchers say

Posted in Stem Cells | Comments Off on Blistering skin disease may be treatable with 'therapeutic reprogramming,' researchers say

CSU Researchers Using Stem Cell Therapy To Treat Kidney Disease In Cats

Posted: November 27, 2014 at 2:44 pm

FORT COLLINS, Colo. (CBS4) Researchers at Colorado State University are using stem cell therapy to treat kidney disease in cats. Theyre hoping to learn if stem cells can stop the progression of the disease.

Its the first feline stem cell program in the country which offers hope for the estimated 75 million pet cats in the U.S.

As cats age, a third or more develop chronic kidney disease. The studies underway at CSU may help both the cats and eventually their humans.

Squeakers (credit: CBS)

Squeakers is a domestic short hair, 15 years old, part Siamese and ill.

Shes actually just recently diagnosed with chronic kidney disease, said veterinarian Dr. Jessica Quimby.

There is no cure for feline kidney disease except a transplant, so Squeakers owner has entrusted her to the veterinarians at CSU.

Her kidneys are a little bit smallish and a little irregular, said Quimby.

For five years, Quimby and her colleagues have been running clinical trials on cats in the early stages of kidney disease. They inject them with stem cells harvested from the fat of healthy cats.

Weve seen variable results. Some kittens do get a little bit improvement in their kidney function, said Quimby. Right after we give the stem cells sometimes its just the same.

Continue reading here:
CSU Researchers Using Stem Cell Therapy To Treat Kidney Disease In Cats

Posted in Cell Therapy | Comments Off on CSU Researchers Using Stem Cell Therapy To Treat Kidney Disease In Cats

Page 1,922«..1020..1,9211,9221,9231,924..1,9301,940..»